KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBT Margin: 2018-2025

Historic EBT Margin for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -0.46%.

  • Castle Biosciences' EBT Margin fell 1012.00% to -0.46% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.51%, marking a year-over-year decrease of 908.00%. This contributed to the annual value of 6.49% for FY2024, which is 3259.00% up from last year.
  • As of Q3 2025, Castle Biosciences' EBT Margin stood at -0.46%, which was down 180.15% from -0.17% recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' EBT Margin peaked at 9.65% during Q3 2024, and registered a low of -91.20% during Q1 2022.
  • For the 3-year period, Castle Biosciences' EBT Margin averaged around -11.63%, with its median value being -3.41% (2024).
  • As far as peak fluctuations go, Castle Biosciences' EBT Margin plummeted by 7,244bps in 2022, and later skyrocketed by 6,603bps in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' EBT Margin stood at -60.53% in 2021, then spiked by 689bps to -53.63% in 2022, then soared by 4,979bps to -3.84% in 2023, then skyrocketed by 1,298bps to 9.14% in 2024, then slumped by 1,012bps to -0.46% in 2025.
  • Its EBT Margin was -0.46% in Q3 2025, compared to -0.17% in Q2 2025 and -29.86% in Q1 2025.